The estimated Net Worth of John Trizzino is at least $8.83 Milion dollars as of 19 August 2024. Mr. Trizzino owns over 655 units of Novavax stock worth over $351,826 and over the last 15 years he sold NVAX stock worth over $7,015,424. In addition, he makes $1,465,600 as Executive Vice President, Chief Commercial Officer a Chief Business Officer at Novavax.
John has made over 40 trades of the Novavax stock since 2011, according to the Form 4 filled with the SEC. Most recently he exercised 655 units of NVAX stock worth $8,050 on 19 August 2024.
The largest trade he's ever made was buying 50,000 units of Novavax stock on 14 May 2018 worth over $82,000. On average, John trades about 7,180 units every 79 days since 2009. As of 19 August 2024 he still owns at least 28,627 units of Novavax stock.
You can see the complete history of Mr. Trizzino stock trades at the bottom of the page.
John J. Trizzino has been appointed as Executive Vice President, Chief Commercial Officer, Chief Business Officer of the Company effective 11/16/2020. He has served as Senior Vice President, Chief Business Officer and Chief Financial Officer and Treasurer since March 2018, and previously served as Senior Vice President, Commercial Operations from March 2014 to March 2018. He previously served as the Company’s Senior Vice President, Business Development from August 2010 to September 2011, and its Senior Vice President, International and Government Alliances from July 2009 to July 2010. Mr. Trizzino was the CEO of ImmunoVaccine. Inc. from September 2011 to September 2013, and, prior to joining the Company, VP, Vaccine Franchise at Medimmune, LLC, Senior Vice President, Business Development at ID Biomedical, and Vice President, Business Development in the Medical Group of Henry Schein, Inc. following his position as Vice President, General Manager of its GIV division. Mr. Trizzino also serves on the board of directors of The Maryland Tech Council. Mr. Trizzino received a B.S. from Long Island University, CW Post and a M.B.A. from New York University.
As the Executive Vice President, Chief Commercial Officer a Chief Business Officer of Novavax, the total compensation of John Trizzino at Novavax is $1,465,600. There are 2 executives at Novavax getting paid more, with Stanley Erck having the highest compensation of $2,438,560.
John Trizzino is 60, he's been the Executive Vice President, Chief Commercial Officer a Chief Business Officer of Novavax since 2020. There are 11 older and 10 younger executives at Novavax. The oldest executive at Novavax, Inc. is Michael McManus, 77, who is the Independent Director.
John's mailing address filed with the SEC is 700 QUINCE ORCHARD ROAD, , GAITHERSBURG, MD, 20878.
Over the last 23 years, insiders at Novavax have traded over $136,088,511 worth of Novavax stock and bought 2,908,869 units worth $5,634,467 . The most active insiders traders include David M Mott, Rajiv I. Modi a Gary C Evans. On average, Novavax executives and independent directors trade stock every 25 days with the average trade being worth of $907,678. The most recent stock trade was executed by John Trizzino on 19 August 2024, trading 655 units of NVAX stock currently worth $8,050.
novavax, inc. is a clinical-stage vaccine company committed to delivering novel products to prevent a broad range of infectious diseases. our recombinant nanoparticles and matrix-m™ adjuvant technology are the foundation for groundbreaking innovation that improves global health through safe and effective vaccines. product pipeline our product pipeline targets a variety of infectious diseases with vaccine candidates currently in clinical development for respiratory syncytial virus ("rsv"), seasonal influenza, pandemic influenza, and ebola virus ("ebov"). we have additional preclinical-stage programs for a variety of infectious diseases. corporate overview novavax is headquartered in gaithersburg, maryland with additional facilities in rockville, maryland and uppsala, sweden. novavax is traded on the nasdaq stock market under the symbol nvax and employs over 300 individuals dedicated to developing novel vaccines to address infectious disease.
Novavax executives and other stock owners filed with the SEC include: